Echinococcus multilocularis vesicular fluid induces the expression of immune checkpoint proteins in vitro.
Animals
Antigens, CD
/ metabolism
B7-H1 Antigen
/ metabolism
CTLA-4 Antigen
/ metabolism
Cytokines
/ immunology
Echinococcosis
/ immunology
Echinococcus multilocularis
/ immunology
Hepatitis A Virus Cellular Receptor 2
/ metabolism
Humans
Killer Cells, Natural
/ immunology
Leukocytes, Mononuclear
/ immunology
Programmed Cell Death 1 Receptor
/ metabolism
Th1 Cells
/ immunology
Th2 Cells
/ immunology
Lymphocyte Activation Gene 3 Protein
Echinococcus multilocularis
CTLA-4
LAG-3
NK cells
PD-1
PD-L1
immune checkpoints
vesicular fluid
Journal
Parasite immunology
ISSN: 1365-3024
Titre abrégé: Parasite Immunol
Pays: England
ID NLM: 7910948
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
09
2019
revised:
21
02
2020
accepted:
10
03
2020
pubmed:
15
3
2020
medline:
8
9
2020
entrez:
15
3
2020
Statut:
ppublish
Résumé
Alveolar echinococcosis is a severe chronic helminthic infection that mimics a tumour-like disease. This study aimed at investigating in vitro interactions between Echinococcus multilocularis vesicular fluid (VF) and different immune checkpoints (PD-1/PD-L1, CTLA-4, LAG-3 and TIM-3). Peripheral blood mononuclear cells (PBMC) from healthy blood donors were isolated by Ficoll. Natural killer (NK) cells were selected. Each type of cell was stimulated individually with E. multilocularis-VF. Expression of the different immune checkpoints was measured by flow cytometry on day 3 and day 6; all supernatants were used for immunoassays. Cells and supernatants from 22 healthy donors were analysed. A significant increase of PD-1, PD-L1, LAG-3 and TIM-3 was observed upon E. multilocularis-VF exposure for NK cells on day 3 (P < .05, Wilcoxon signed-rank test). A significant increase of PD-L1 and CTLA-4 was observed upon E. multilocularis-VF exposure for T cells on day 6 (P < .05, Wilcoxon signed-rank test), which was associated with increased levels of Th1 and Th2 cytokines P < .05, Wilcoxon signed-rank test). These preliminary data suggest that immune checkpoints could be a way for E. multilocularis to modulate the host immune response during alveolar echinococcosis.
Substances chimiques
Antigens, CD
0
B7-H1 Antigen
0
CD274 protein, human
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Cytokines
0
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Lymphocyte Activation Gene 3 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12711Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Torgerson PR, Keller K, Magnotta M, Ragland N. The global burden of alveolar echinococcosis. PLoS Negl Trop Dis. 2010;4(6):e722.
Wang J, Gottstein B. Immunoregulation in larval Echinococcus multilocularis infection. Parasite Immunol. 2016;38:182-192.
Hernández A, O'Connor JE, Mir A. Phenotypic analysis of peripheral lymphocyte subpopulations in hydatid patients. Parasitol Res. 1999;85(11):948-950.
Bellanger AP, Mougey V, Pallandre JR, Gbaguidi-Haore H, Godet Y, Millon L. Echinococcus multilocularis vesicular fluid inhibits activation and proliferation of natural killer cells. Folia Parasitol (Praha). 2017;64;pii: 2017.029.
Moretta L, Pietra G, Vacca P, et al. Human NK cells: From surface receptors to clinical applications. Immunol Lett. 2016;178:15-19.
Hemphill A, Stadelmann B, Rufener R, et al. Treatment of echinococcosis: albendazole and mebendazole-what else? Parasite. 2014;21:70.
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Next generation immune-checkpoints for cancer therapy. J Thorac Dis. 2018;10(Suppl 13):S1581-S1601.
La X, Zhang F, Li Y, et al. Upregulation of PD-1 on CD4⁺CD25⁺ T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis. Int Immunopharmacol. 2015;26(2):357-366.
Wang J, Jeddawi F, Bellanger AP, Beldi G, Millon L, Gottstein B. Control of alveolar echinococcosis via PD1/PDL1 blockade in mice. Parasite Immunol. 2018;40(12):e12596.
Bellanger AP, Pallandre JR, Gbaguidi-Haore H, et al. Investigating the impact of Echinococcus multilocularis vesicular fluid on human cells from healthy blood donors. J Immunol Methods. 2015;417:52-59.
Li J, Jie HB, Lei Y, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518.
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434-452.
Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
Vuitton DA, Bresson-Hadni S, Laroche L, et al. Cellular immune response in Echinococcus multilocularis infection in humans. II. Natural killer cell activity and cell subpopulations in the blood and in the periparasitic granuloma of patients with alveolar echinococcosis. Clin Exp Immunol. 1989;78(1):67-74.
Zhang S, Hüe S, Sène D, et al. Expression of major histocompatibility complex class I chain-related molecule A, NKG2D, and transforming growth factor-beta in the liver of humans with alveolar echinococcosis: new actors in the tolerance to parasites? J Infect Dis. 2008;197(9):1341-1349.
Gottstein B, Soboslay P, Ortona E, Wang J, Siracusano A, Vuitton DΑ. Immunology of Alveolar and Cystic Echinococcosis (AE and CE). Adv Parasitol. 2017;96:1-54.
Li Y, Xiao Y, Su M, et al. Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis. Exp Ther Med. 2016;11(1):251-256.
Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765-779.
Zhang C, Lin R, Li Z, et al. Immune exhaustion of T cells in alveolar echinococcosis patients and its reversal by blocking checkpoint receptor TIGIT in a murine model. Hepatology. 2019. https://doi.org/10.1002/hep.30896. [Epub ahead of print].